A novel thinking: DDR axis refines the classification of ccRCC with distinctive prognosis, multi omics landscape and management strategy

Aimin Jiang(Second Military Medical University), Linhui Wang(Second Military Medical University), Le Qu(Nanjing General Hospital of Nanjing Military Command), Jiaao Song(Second Military Medical University), Bing Liu(Central South University), Zheng Wang(Shanghai Jiao Tong University), Xiao Fang(Merck & Co., Inc., Rahway, NJ, USA (United States)), Peng Luo(Zhujiang Hospital), Zhenjie Wu(Second Military Medical University), Yu Fang(Second Military Medical University)
Frontiers in Public Health
November 21, 2022
10.3389/fpubh.2022.1029509
Cited by 9

Related Papers

Exosome-Transmitted lncARSR Promotes Sunitinib Resistance in Renal Cancer by Acting as a Competing Endogenous RNA
|Cancer Cell|2016|1.2k
Impact of Examined Lymph Node Count on Precise Staging and Long-Term Survival of Resected Non–Small-Cell Lung Cancer: A Population Study of the US SEER Database and a Chinese Multi-Institutional Registry
|Journal of Clinical Oncology|2017|358
Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study
|Clinical Cancer Research|2018|355
Neoadjuvant and adjuvant pembrolizumab plus chemotherapy in locally advanced gastric or gastro-oesophageal cancer (KEYNOTE-585): an interim analysis of the multicentre, double-blind, randomised phase 3 study
|The Lancet Oncology|2023|336
Long-Term Outcomes in KEYNOTE-052: Phase II Study Investigating First-Line Pembrolizumab in Cisplatin-Ineligible Patients With Locally Advanced or Metastatic Urothelial Cancer
|Journal of Clinical Oncology|2020|292